

Supplementary Table 2. Comparison of total kidney volume growth rate (%/year) between clinical trials

| Mayo imaging classification | TEMPO 3:4 trial | | ESSENTIAL trial | KNOW-CKD trial |
|-----------------------------|------------------------|----------------------|------------------------|--------------------------------|
| | Tolvaptan (n = 787) | Placebo (n = 441) | Tolvaptan (n = 108) | Without tolvaptan (n = 178) |
| 1A | | | | 1.22 (-0.3 to 2.73) |
| 1B | 1.23 (0.30–2.17) | 3.25 (1.50–5.03) | | 3.83 (2.62–5.05) |
| 1C | 1.79 (1.26–2.32) | 5.12 (4.35–5.90) | 2.90 | 5.26 (4.16–6.36) |
| 1D | 3.03 (2.47–3.59) | 5.62 (4.58–6.68) | 4.55 | 9.39 (5.3–13.49) |
| 1E | 4.96 (4.03–5.89) | 7.75 (6.16–9.35) | 6.60 | 11.72 (6.84–16.59) |

Data are expressed as mean (95% CI).

ESSENTIAL, Evaluating the Safety and effectiveness in adult KorEaN patients treated with Tolvaptan for management of autosomal dominant polycystic kidney disease; KNOW-CKD, KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease; TEMPO 3:4, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4.